Trial Profile
Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Symptomatic Pulmonary Hypertension Associated With Sickle Cell Disease
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bosentan (Primary)
- Indications Pulmonary hypertension
- Focus Registrational; Therapeutic Use
- Acronyms ASSET 2
- Sponsors Actelion Pharmaceuticals
- 15 Apr 2014 New trial record
- 15 Apr 2014 New trial record
- 12 Feb 2010